Development of New Plasma-Derived Pharmaceutical Product Portfolio This Year

Clinical Phases and References for New Drug Monograph Registration

The initial focus of our production lines has been on the sustainable supply of 20% Albumin (Albugin) and 5% Intravenous Immunoglobulin (Immunogin). With the completion of clinical stability studies and the registration of technical dossiers (CTD), this year we will witness the entry of Factor VIII coagulation products and specific immunoglobulins (such as Anti-Hepatitis B and Anti-Tetanus) into the country’s hospital distribution chain.

Continuous enhancement of the variety of the biological product portfolio minimizes the need to import licensed products.

Vision for National Hemodynamic Self-Sufficiency

Nojin’s clinical development program, utilizing localized clinical trial data and continuous Pharmacovigilance, guarantees 100% safety of the new pharmaceutical portfolio in post-marketing phases (Phase IV).